法国全国性研究:主动脉瓣狭窄置换术的趋势
基于法国2007至2019年住院数据库,共纳入106 253例单纯外科主动脉瓣置换(SAVR)、46 514例联合SAVR和65 651例经导管主动脉瓣置换(TAVR)。主动脉瓣置换总数从10 892例增至23 109例,TAVR大幅增长而SAVR在2013年后下降;在75岁及以上患者中,近3年TAVR院内死亡率与单纯SAVR相似或更低。
要点
- 十年间主动脉瓣置换总数翻倍,2018年TAVR成为主要术式。
- 75岁及以上患者,TAVR应视为首选治疗。
- TAVR永久起搏器植入率仍高,住院时间中位6天。
核心结论
- 十年间主动脉瓣置换总数翻倍,TAVR在2018年成为主导术式。
- 在75岁及以上患者中,TAVR应作为首选考虑。
- TAVR永久起搏器植入率仍高,住院时间仍较长。
研究设计与样本
- 基于法国行政医院出院数据库的全国性队列研究,纳入2007至2019年因主动脉瓣狭窄行主动脉瓣置换的所有连续患者。
- 共纳入106 253例单纯SAVR(49%)、46 514例联合SAVR(21%)和65 651例TAVR(30%)。
主要发现
- 主动脉瓣置换总数从2007年10 892例线性增至2019年23 109例(趋势P<0.0001)。
- TAVR从253例增至13 030例(趋势P<0.0001),SAVR在2013年达12 699例后降至2019年10 079例。
- SAVR和TAVR的院内死亡率均下降(趋势P均<0.0001)。
- 2017至2019年,75岁及以上患者中TAVR院内死亡率与单纯SAVR相似或更低。
- 2017至2019年TAVR永久起搏器植入率为16.7%,住院时间中位6天。
临床怎么用
- 75岁及以上主动脉瓣狭窄患者,TAVR应作为首选治疗方式考虑。
- 需关注TAVR后永久起搏器植入风险及住院时间管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Transcatheter aortic valve replacement (TAVR) as an alternative to surgical aortic valve replacement (SAVR) has profoundly changed the management of patients with aortic valve stenosis (AS). Large unbiased nationwide data regarding TAVR implementation, impact on SAVR and their respective outcomes are scarce. METHODS AND RESULTS: Based on a French administrative hospital-discharge database, we collected data on all consecutive aortic valve replacements (AVRs) performed in France for AS between 2007 and 2019 [106 253 isolated SAVR (49%), 46 514 combined SAVR (21%), and 65 651 TAVR (30%)]. The number of AVR linearly increased between 2007 and 2019 (from 10 892 to 23 109, P for trend < 0.0001) due to a marked increase in TAVR (from 253 to 13 030, P for trend < 0.0001), while SAVR increased up to 2013 and then declined (10 892 in 2007, 12 699 in 2013, and 10 079 in 2019). The Charlson index decreased linearly for TAVR, but in two steps for SAVR (2011 and 2017). In-hospital mortality rates of both SAVR and TAVR declined (both P for trend < 0.0001) and were similar or lower for TAVR than for isolated SAVR in patients 75 years or above in the last 3 years (2017-19). Complication rates of TAVR also declined but permanent pacemaker rates remained high and length of stay substantial (16.7% and median 6 days, respectively, in 2017-19). CONCLUSION: The number of AVR has doubled in a decade and TAVR has become the dominant form of AVR in 2018. The improvement in patient profiles seems to have anticipated the demonstrated benefit of TAVR in intermediate and low-risk patients. In patients 75 years or older, TAVR should be considered as the first option. We also highlight two important areas for improvement, the high permanent pacemaker rates, and the long length of stay even in the contemporary era. Our results may have major implications for clinical practice and policymakers.
引用
- Nguyen V, Willner N, Eltchaninoff H, et al. Trends in aortic valve replacement for aortic stenosis: a French nationwide study. Eur Heart J. 2022. PMID: 34849714. doi:10.1093/eurheartj/ehab773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。